David Hung, Nuvation Bio president and CEO (website via Vimeo)
David Hung's Nuvation Bio axes clinical program, lays off 30 after researchers say they can't manage the side effects
The latest biotech to sound the alarm comes from a David Hung startup, and it comes a little over a month after receiving a series …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
